Larvol Delta - Progress-on-14-key-opportunities-expected-to-launch-20252031-each-with-PYS-potential-above-1632-billion

efimosfermin alfa (GSK6519754) - GSK

depemokimab (GSK3511294) - GSK

GSK5764227 - GSK

GSK6042981 - GSK

https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-continued-strong-performance/

Jul 31, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next